NO20020983D0 - Metoder og blandinger til administrasjon av terapeutiske midler - Google Patents

Metoder og blandinger til administrasjon av terapeutiske midler

Info

Publication number
NO20020983D0
NO20020983D0 NO20020983A NO20020983A NO20020983D0 NO 20020983 D0 NO20020983 D0 NO 20020983D0 NO 20020983 A NO20020983 A NO 20020983A NO 20020983 A NO20020983 A NO 20020983A NO 20020983 D0 NO20020983 D0 NO 20020983D0
Authority
NO
Norway
Prior art keywords
methods
cationic
compositions
cells
solubilized
Prior art date
Application number
NO20020983A
Other languages
English (en)
Other versions
NO20020983L (no
NO329773B1 (no
Inventor
Kesavan Esuvaranathan
Ratha Mahendran
Carmel Lawrencia
Original Assignee
Genecure Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genecure Pte Ltd filed Critical Genecure Pte Ltd
Publication of NO20020983D0 publication Critical patent/NO20020983D0/no
Publication of NO20020983L publication Critical patent/NO20020983L/no
Publication of NO329773B1 publication Critical patent/NO329773B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20020983A 1999-09-01 2002-02-27 In vitro fremgangsmate for transfeksjon av et polynukleotid inn i celler, et transfeksjonsmiddel og en farmasoytisk sammensetning. NO329773B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ2593A AUPQ259399A0 (en) 1999-09-01 1999-09-01 Therapeutic agents
PCT/SG2000/000130 WO2001015755A2 (en) 1999-09-01 2000-09-01 Methods and compositions for delivery of pharmaceutical agents

Publications (3)

Publication Number Publication Date
NO20020983D0 true NO20020983D0 (no) 2002-02-27
NO20020983L NO20020983L (no) 2002-04-24
NO329773B1 NO329773B1 (no) 2010-12-13

Family

ID=3816764

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020983A NO329773B1 (no) 1999-09-01 2002-02-27 In vitro fremgangsmate for transfeksjon av et polynukleotid inn i celler, et transfeksjonsmiddel og en farmasoytisk sammensetning.

Country Status (11)

Country Link
US (2) US7320963B2 (no)
EP (1) EP1208218B1 (no)
JP (1) JP4995388B2 (no)
AT (1) ATE292187T1 (no)
AU (2) AUPQ259399A0 (no)
CA (1) CA2384425C (no)
DE (1) DE60019134T2 (no)
ES (1) ES2240157T3 (no)
NO (1) NO329773B1 (no)
TW (1) TWI262085B (no)
WO (1) WO2001015755A2 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ259399A0 (en) * 1999-09-01 1999-09-23 Lustre Investments Pte Ltd Therapeutic agents
EP1233671A4 (en) * 1999-11-29 2005-11-02 Mirus Corp COMPOSITIONS AND METHODS OF DISPOSING MEDICAMENTS USING AMPHIPHILIC BINDING MOLECULARS
WO2003038103A1 (en) * 2001-10-29 2003-05-08 Atso Raasmaja Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers
US7153905B2 (en) * 2003-03-21 2006-12-26 The General Hospital Corporation Hyperbranched dendron and methods of synthesis and use thereof
US8545830B2 (en) * 2003-03-24 2013-10-01 University Of Tennessee Research Foundation Multi-functional polymeric materials and their uses
JP4649571B2 (ja) * 2003-07-16 2011-03-09 英俊 有馬 細胞にｒｎａを導入する方法
CA2971062C (en) 2004-08-16 2019-02-26 Cellresearch Corporation Pte Ltd Isolation of stem/progenitor cells from amniotic membrane of umbilical cord
US9346029B2 (en) 2005-06-06 2016-05-24 The University Of British Columbia Polymer-based serum albumin substitute
WO2007046775A1 (en) 2005-10-21 2007-04-26 Cellresearch Corporation Pte Ltd Isolation and cultivation of stem/progenitor cells from the amniotic membrane of umbilical cord and uses of cells differentiated therefrom
ITMI20071173A1 (it) * 2007-06-11 2008-12-12 Univ Degli Studi Milano Polimeri iperramificati a base di ciclodestrine e poli(amidoammine) per il rilascio controllato di farmaci insolubili
BR112012021991A2 (pt) 2010-03-01 2020-09-01 The University Of British Columbia policlicerol hiperramificado uso de um poliglicerol hipermanificado, método de adiministração de uma força biologicamente ativa a um tecido biológico, composição farmacêutica e método de síntese de um poliglicerol hiperrramificado.
EP2646107A2 (en) 2010-12-01 2013-10-09 Spinal Modulation Inc. Agent delivery systems for selective neuromodulation
WO2013074526A2 (en) 2011-11-15 2013-05-23 Byocoat Enterprises, Inc. Antimicrobial compositions and methods of use thereof
WO2014025795A1 (en) 2012-08-07 2014-02-13 Northeastern University Compositions for the delivery of rna and drugs into cells
EP3012263B1 (en) * 2013-06-21 2017-11-15 The Catholic University of Korea Industry-Academic Cooperation Foundation Reducing or non-reducing polynucleotide polymer for drug delivery and method for preparing same
JP6707461B2 (ja) 2014-03-27 2020-06-10 ソーク インスティテュート フォー バイオロジカル スタディーズ １型および２型糖尿病ならびに関連障害を治療するための組成物および方法
WO2016138464A1 (en) 2015-02-27 2016-09-01 Salk Institute For Biological Studies Reprogramming progenitor compositions and methods of use therefore
JP7178264B2 (ja) 2016-05-25 2022-11-25 ソーク インスティチュート フォー バイオロジカル スタディーズ オルガノイド作製および疾患モデル化のための組成物および方法
CN106924746B (zh) * 2017-03-03 2020-11-03 中山大学 复合基因载体及其应用
WO2019115472A1 (en) 2017-12-11 2019-06-20 Fondazione Istituto Firc Di Oncologia Molecolare (Ifom) Polycomb inhibitors and uses thereof
WO2020168244A1 (en) 2019-02-15 2020-08-20 Incelldx, Inc. Assaying bladder-associated samples, identifying and treating bladder-associated neoplasia, and kits for use therein
CN113181119B (zh) * 2021-05-08 2023-08-29 深圳市第二人民医院(深圳市转化医学研究院) 载药系统及其制备方法、药物组合物
CN113082001B (zh) * 2021-05-25 2023-05-26 中国科学院广州生物医药与健康研究院 一种核酸递送系统及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
JP3545403B2 (ja) 1993-04-22 2004-07-21 スカイファルマ インコーポレイテッド 医薬化合物を被包しているシクロデキストリンリポソーム及びその使用法
US5614503A (en) 1993-11-12 1997-03-25 Aronex Pharmaceuticals, Inc. Amphipathic nucleic acid transporter
US5691316A (en) 1994-06-01 1997-11-25 Hybridon, Inc. Cyclodextrin cellular delivery system for oligonucleotides
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5993850A (en) 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
JPH11508231A (ja) 1995-05-26 1999-07-21 ソマティックス セラピー コーポレイション 安定な脂質／核酸複合体を含む送達ビヒクル
US5932241A (en) 1995-06-07 1999-08-03 Valentis, Incorporated Cationic lipid DNA complexes for gene targeting
US5830878A (en) 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
WO1998013026A1 (en) * 1997-06-10 1998-04-02 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
DE69708919T2 (de) 1996-08-19 2002-06-27 Us Gov Nat Inst Health Neue liposomkomplexe mit erhöhter systemischer verabreichung
AU1987197A (en) * 1997-03-10 1998-09-29 Heather Lynn Davis Gene delivery to mucosal epithelium for immunization or therapeutic purpose
WO1998044909A1 (en) 1997-04-04 1998-10-15 Valentis Inc. Improved methods of delivery using cationic lipids and helper lipids
WO1998051285A2 (en) * 1997-05-15 1998-11-19 Genzyme Corporation Cationic amphiphile formulations
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
AU9404398A (en) 1997-09-23 1999-04-12 Megabios Corporation Methods for preparing lipids/polynucleotide transfection complexes
AUPQ259399A0 (en) * 1999-09-01 1999-09-23 Lustre Investments Pte Ltd Therapeutic agents
JP2003519199A (ja) * 1999-12-30 2003-06-17 ノバルティス アクチエンゲゼルシャフト 遺伝子治療のための新規なコロイド合成ベクター

Also Published As

Publication number Publication date
US20020146830A1 (en) 2002-10-10
CA2384425A1 (en) 2001-03-08
ES2240157T3 (es) 2005-10-16
TWI262085B (en) 2006-09-21
US20090054364A1 (en) 2009-02-26
WO2001015755A2 (en) 2001-03-08
AUPQ259399A0 (en) 1999-09-23
JP4995388B2 (ja) 2012-08-08
DE60019134T2 (de) 2006-02-09
CA2384425C (en) 2011-01-25
EP1208218B1 (en) 2005-03-30
ATE292187T1 (de) 2005-04-15
US7320963B2 (en) 2008-01-22
DE60019134D1 (de) 2005-05-04
AU7327500A (en) 2001-03-26
JP2003508456A (ja) 2003-03-04
EP1208218A2 (en) 2002-05-29
AU781684B2 (en) 2005-06-09
NO20020983L (no) 2002-04-24
NO329773B1 (no) 2010-12-13
WO2001015755A3 (en) 2002-02-28
US7709457B2 (en) 2010-05-04

Similar Documents

Publication Publication Date Title
NO20020983D0 (no) Metoder og blandinger til administrasjon av terapeutiske midler
Yin et al. In situ transforming RNA nanovaccines from polyethylenimine functionalized graphene oxide hydrogel for durable cancer immunotherapy
Phuengkham et al. A designer scaffold with immune nanoconverters for reverting immunosuppression and enhancing immune checkpoint blockade therapy
Hou et al. Engineering stimuli‐activatable boolean logic prodrug nanoparticles for combination cancer immunotherapy
Dai et al. Red blood cell membrane-camouflaged nanoparticles loaded with AIEgen and Poly (I: C) for enhanced tumoral photodynamic-immunotherapy
Furgeson et al. Modified linear polyethylenimine− cholesterol conjugates for DNA complexation
Tran et al. Modulation of macrophage functional polarity towards anti-inflammatory phenotype with plasmid DNA delivery in CD44 targeting hyaluronic acid nanoparticles
Oishi et al. pH-responsive three-layered PEGylated polyplex micelle based on a lactosylated ABC triblock copolymer as a targetable and endosome-disruptive nonviral gene vector
Li et al. Charge-convertible polymers for improved tumor targeting and enhanced therapy
Kim et al. MMPs-responsive release of DNA from electrospun nanofibrous matrix for local gene therapy: in vitro and in vivo evaluation
Nukolova et al. LHRH-targeted nanogels as a delivery system for cisplatin to ovarian cancer
Zeng et al. Manipulation of transgene expression in fibroblast cells by a multifunctional linear-branched hybrid poly (β-amino ester) synthesized through an oligomer combination approach
Chen et al. Synthesis and properties of star-comb polymers and their doxorubicin conjugates
Fewell et al. Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer
Li et al. Single micelle vectors based on lipid/block copolymer compositions as mRNA formulations for efficient cancer immunogene therapy
Zheng et al. Targeted co-delivery biomimetic nanoparticles reverse macrophage polarization for enhanced rheumatoid arthritis therapy
Jindal et al. Nanomaterials-mediated immunomodulation for cancer therapeutics
Fewell et al. Treatment of disseminated ovarian cancer using nonviral interleukin‐12 gene therapy delivered intraperitoneally
Yang et al. Multifunctional silica nanocomposites prime tumoricidal immunity for efficient cancer immunotherapy
Li et al. In situ injectable hydrogel-loaded drugs induce anti-tumor immune responses in melanoma immunochemotherapy
Ferruti et al. Prevailingly cationic agmatine-based amphoteric polyamidoamine as a nontoxic, nonhemolytic, and “stealthlike” DNA complexing agent and transfection promoter
Marzi et al. Hydrogels as promising therapeutic strategy for the treatment of skin cancer
US20180339053A1 (en) Use of 1,2-dicarboxylic acid monoamide polymer as synergist for chemotherapy
Zhang et al. Targeted delivery of dasatinib to deplete tumor-associated macrophages by mannosylated mixed micelles for tumor immunotherapy
Neshat et al. Polymeric nanoparticle gel for intracellular mRNA delivery and immunological reprogramming of tumors

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees